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The protective immunity resulting from exposure to nontuberculous mycobacteria (NTM), BCG and
virulent mycobacteria in different sequences was studied in the guineapig model employing strains
prevalent in the south Indian BCG trial area and time kinetics to observe the immuno-modulation. The
findings suggest that during the early course of challenge infection in guineapigs there was no
interference with the immunity due to BCG, by prior exposure to NTM. In the animals sensitised with
M. avium intracellulare b fore immunisation, the challenge infection was localised and confined to the
site of inoculation, and only a few organisms reached the spleen.. However, at the later stages of the
infection, as seen by the spleen viable counts at 12 wk, it appeared that the barrier at the localised site of
infection may not be intact in the animals with prior exposure to NTM, and a few organisms disseminate
to the spleen.
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Interactions with the immune responses to other
mycobacterial infections still remains one of the
most popular explanations for BCG’s varying
efficacy1,2. Palmer and associates3’4 showed in
animal experiments, and in studies of US Navy
personnel,that infections with certain non-
tuberculous mycobacteria (NTM) could impart
some protection against infection with the tubercle
bacillus and such naturally acquired protection
could mask the protection due to BCG vaccination.
In 1970, Abrahams5 pointed out that the first
mycobacterial infection may set the antigenic
reaction pattern and in the 1980s Stanford, Rook
and associates6-8 proposed that exposure to NTM
could result in two types of cell-mediated responses,
the ‘Listeria type’ and the ‘Koch type’. Which of
thes  two types of responses is evoked depended,
among other factors, on the mycobacterial species
inducing the response and the immunomodulating
cells and the pathway brought into play. They
further proposed that the ‘Listeria type’ of response
enhances the protective effect of subsequent
v ccination with BCG while the ‘Koch type’ response
opposes the protective effect of BCG. BCG vaccina-
tion of a person with a pre-existing Koch-like
response will temporarily boost this response, but
completely fail to reconvert to Listeria-like respon-
siveness or induce protection from pathogenic chal-
lenge. According to them, this is likely to have been
the situation in the south Indian tria19,10. However,
attempts by others to demonstrate that prior
infection with any of the mycobacteria induced a
suppressive effect against BCG have failed11-14.
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The findings of Raj Narain et al15 that there is
widespread sensitisation to PPD-B in the BCG
trial area of south India, and the findings of
Paramasivan et a116 that Mycobacterium avium-
intracellulare-scrofulaceum (MAIS) strains are
among the most frequently isolated from the
sputum of patients from this area suggest the
possibility that MAIS strains may be widely
prevalent in this region. Also, nearly 70 per cent
of M. tuberculosis olates from this area are of
low virulence for guineapigs and have been
designated as the south Indian variant (SIV)17-20.
Exposure of the population in this area to these
NTM, BCG and M. tuberculosis very likely to
be occurring in different possible sequences. The
present study was undertaken in the guineapig
model employing strains prevalent in the region
and to examine the time kinetics with reference to
the protective immunity resulting from such an
exposure.
Material & Methods
Animals : Twenty four random-bred guineapigs of
the M-strain21 from the animal house of the
Tuberculosis Research Centre (TRC), Madras
were used in this experiment.
The guineapigs were divided into five groups,
groups A to E, with 6 animals in groups C to E,
and 3 each in groups A and B since they did not
have further subgroups.
Strains of mycobacteria: The strains of
mycobacteria used in the experiment were, M.
avium intracellulare (standard TMC strain 1403
maintained at TRC), M. scrofulaceum strain
isolated from a patient and maintained at TRC),
BCG (standard strain Glaxo maintained at TRC)
and M. tuberculosis outh Indian variant (strain
isolated from a south Indian patient before
treatment and maintained at TRC).
Preparation of the inoculum : Growth from
Lowenstein Jensen (LJ) slope was inoculated into
Middlebrook’s 7H9 liquid medium (Difco) con-
taining albumin and dextrose. The 7H9 cultures
were incubated for 2 wk at 37°C, centrifuged at
3000 rpm (Beckman J-6B) for 20 min at room
temperature and the pellet was resuspended in
sterile saline (0.85%) containing 0.05 per cent
Tween 80. The total number of organisms per ml
in  th is  suspension was counted under  the
microscope using a Thoma bacterial counting
chamber (Gallenkamp, London) and was adjusted
to 5 x 106/ml using Tween saline to prepare the
standard suspensions for inoculation. After
preparation, the suspensions were distributed into
glass universals in 5 ml aliquots and stored at
-20°C until use.
Sensitisation, immunisation and challenge : For
sensitisation, immunisation and challenge, inocula
containing a total number of 1 x 106 (total count)
of each organism in 0.2 ml saline with Tween
(0.05%) were given subcutaneously to the
guineapigs on the inner side of the thigh. Different
sensitisation, immunisation and challenge schedules
were followed for each group of guineapigs as
shown in Table I. The guineapigs in group A were
not subjected to prior sensitisation or immunisation
but were directly injected with M. tuberculosis
south Indian variant (SIV). The guineapigs in
group B were first immunised with BCG. After six
wk, they were injected with SIV. The guineapigs
in group C were also first immunised with BCG.
After six wk, half of these animals were given
M. avium intracellulare (Mai) and the others
were given M. scrofulaceum. After another six
wk, they were injected with SIV. Half of the
guineapigs in group D were sensitised with Mai,
Table I. Experimental design for viable count in spleen at 12
wk after challenge
Week Group A Group B Group C Group D Group E
0 SIV BCG BCG NTM NTM
1 1 1 1 1
6 None SIV NTM SIV BCG
1 1 1 I 1
12 VC 1 SIV 1 SIV
1 1 1 1
18 VC 1 VC 1
1 I
24 VC VC
SIV, M. tuberculosis south Indian strain
NTM, nontuberculous mycobacteria (M. avium intracellu-
lare/ M. scrofulaceum)
VC, viable count in spleen
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and the other half with M. scrofulaceum first.
After six wk, they were injected with SIV. The
animals in group E were also sensitised with Mai
or M. scrofulaceum first. After six weeks they
were given BCG and after another six wk they
were infected with SIV.
Sacrifice and spleen viable count : The guineapigs
were sacrificed using chloroform vapour 12 wk after
challenge. Autopsy was done. A portion of the
spleen was collected and homogenised in 5 ml sterile
distilled water in a motor driven teflon/glass
grinder. Viable count was set up on LJ using 10 µl of
this neat suspension and 5 serial ten-fold dilutions,
and colony forming units (cfu) per spleen were
calculated. From this, the average cfu/spleen for
each subgroup was calculated. The organisms
recovered from the spleen in the viable count culture
were confirmed to be M. tuberculosis by niacin test.
Time kinetics experiments : To examine the
kinetics of the early course of challenge infection
this experiment was undertaken.
Guineapigs : Twenty four random-bred M-strain
guineapigs from the animal house of TRC were
used in this experiment. These were divided into
three groups with 8 animals in each group.
Preparation of the inoculum : The suspension for
inoculation was prepared fresh every time.
Growth from 2 wk old cultures of the strains on
LJ was transferred with a wire loop to pre-
weighed Bijou bottles containing 0.2 ml sterile
distilled water and glass beads. The bottles were
weighed again to calculate the weight of the
organisms, shaken for 1 min in a mechanical
shaker and the resulting suspension was diluted
using sterile distilled water to contain 1 mg of the
organism in the required volume.
Sensitisation, immunisation and challenge sche-
dule: For sensitisation and immunisation, 1 mg
moist weight of the organism in 0.1 ml sterile
distilled water was injected intradermally in the
inner side of the thigh. For challenging, 1 mg
moist weight of the challenge organism in 0.5 ml
sterile distilled water was injected intramuscularly
into the thigh. The sensitisation, immunisation
and challenge schedule followed for each group of
guineapigs is shown in Table Il. The guineapigs in
group 1 served as controls and were challenged with
M. tuberculosis south Indian low virulent strain
(SIV) without prior sensitisation or immunisation.
The guineapigs in group 2 were immunised first
with BCG. After 6 wk, these animals were
challenged with SIV. The guineapigs in group 3
were sensitised first by injecting with Mai. After 6
wk, these animals were given BCG, and 6 wk later
were challenged with SIV.
Skin tests : All the guineapigs used in the time
kinetics experiment were skin tested with 5 µg of
PPD-RT22 in 0.1 ml normal saline one wk before
they were challenged.The skin test was
administered on the dorsal side of the animal after
shaving the selected area. The skin test readings
were taken at 48 h.
Sacrifice and spleen viable counts : At 2, 4, 6 and
8 wk after challenge,two animals from each
subgroup were sacrificed. Spleen viable counts
were set up as before.
Statistical analysis : Student’s ‘t’ test was used to
test the differences in the mean cfu in the spleen
between groups,. and to test the significance of
co relation coefficient between skin test reactivity
and cfu in spleen.
Results
The viable count in the spleen 12 wk after
challenge are given in Table III. In the control
animals challengedwith SIV without prior
sensitisation or immunisation, 5.56 log colony
forming units (cfu) could be recovered from the
spleen 12 wk after challenge. While none of the
animals which had been immunised with BCG
Table II. Experimental design for kinetics of challenge
infection
Week Group 1 Group 2 Group 3
0 Mai
6 BCG BCG
12 SIV SIV SIV
14-20 VC VC VC
SIV, M. tuberculosis south Indian strain
VC, viable count in spleen, these were studied at 2, 4, 6, 8 wk
after challenge
Mai, M. avium intracellulare
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Table III. Viable counts in the spleen of guineapigs 12 wk
after challenge with M. tuberculosis south Indian strain
Guinea- Group cfu in Mean cfu (log) in
pig no. spleen spleen/ group
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SIV 1077000
SIV 8620
SIV 0
BCG-SIV 0
BCG-SIV 0
BCG-SIV 0
Mai-SIV 0
Mai-SIV 431
Mai-SIV 0
Msc-SIV 0
Msc-SIV 646
Msc-SIV 0
BCG-Mai-SIV 0
BCG-Mai-SIV 0
BCG-Mai-SIV 0
BCG-Msc-SIV
BCG-Msc-SIV
BCG-Msc-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Msc-BCG-SIV
Msc-BCG-SIV
Msc-BCG-SIV
0
0
0
0
0
431
0
215
431
5.56
0.00*
2.16
2.33
0.00*
0.00*
2.16
2.33
SIV, M. tuberculosis south Indian strain
Mai, M. avium intracellulare
Msc, M. scrofulaceum
cfu, colony forming units
* 0.00 actually means that there was no growth in culture and
implies that the log cfu in spleen was less than 1.85 which was
the minimum detectable level in these experiments
before challenge (BCG-SIV) had detectable
number of organisms in the spleen 12 wk after
challenge, those which had been given Mai, or
M. scrofulaceum before challenge (Mai-SIV and
Msc-SIV) had log cfu of 2.16 and 2.33,
respectively. These numbers, however, were very
much lower than the number of organisms (5.56
log cfu) recovered from the spleens of control
animals challenged directly with a similar dose of
SJV.
Among the animals challenged after they had
been given BCG followed by NTM, or NTM
followed by BCG, none of the animals which
were exposed to BCG first had detectable number
of organisms in the spleen 12 wk after challenge.
On the other hand, among the animals exposed to
NTM first, the animals exposed to Mai first (Mai-
BCG-SIV) had log cfu of 2.16, and animals
exposed to M. scrofulaceum first (Msc-BCG-SIV)
had log cfu of 2.33 in the spleen 12 wk after
challenge.
However, none of the differences between the
different groups of guineapigs in the number of
viable organisms in the spleen at 12 wk after
challenge, were statistically significant (P < 0.05).
Time kinetics experiments: Skin test : The results
of the skin test reactivity to PPD-RT22 are given
in Table IV. The skin test reactivity before
challenge was minimal (1.94 mm) in animals
which had not been exposed to any mycobacteria.
In the animals exposed to BCG alone, and in the
animals exposed to Mai and BCG, the skin test
responsewas high (8.69 mm and 10.5 mm,
respectively).
Viable count in spleen: In the animals directly
challenged with SIV, the maximum number of
organisms (4.23 log cfu) was seen in the spleen at
2 wk after challenge. The number of organisms in
the spleen was lower at 4 wk (2.44 log cfu) and
became undetectable by 6 wk (Table IV). In the
animals challenged with SIV after they had been
immunised with BCG (BCG-SIV), or sensitised
with Mai and then immunised with BCG (Mai-
BCG-SIV) also, the maximum viable counts were
seen at 2 wk after challenge (3.10 and 2.99 log cfu,
respectively). These numbers, however, were
significantly less (P < 0.05) than the maximum log
viable counts in the directly challenged animals.
The challenge organisms could not be detected in
the spleen 6 wk after, challenge in animals
immunised with BCG (BCG-SIV) and by the 4th
wk itself in animals which were sensitised with
Mai before immunisation with BCG (Mai-
BCG-SIV).
A significant negative correlation was observed
between skin test reactivity to PPD-RT22 at 48 h
and viable count in spleen at 2 wk after challenge
(r = 0.94; P < 0.05).
Discussion
The findings of the present study indicate that
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Table IV. Time kinetics - viable count in spleen of guineapigs challenged with M. tuberculosis south Indian strain
Guinea- Group Skin test Viable count in spleen
pig no. reading (mm) Time after cfu in Mean cfu (log)
challenge (wk) spleen in spleen
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SIV
SIV
SIV
SIV
SIV
SIV
SIV
SIV
Mean skin test
reactivity (mm)
BCG-SIV
BCG-SIV
BCG-SIV
BCG-SIV
BCG-SIV
BCG-SIV
BCG-SIV
BCG-SIV
Mean skin test
reactivity (mm)
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mai-BCG-SIV
Mean skin test
reactivity (mm)
2
0
2
0
2.5
3
2
4
1.94
9
12.5
12
12
7
8
4
5
8.69
7
13
9
12
10
10
11
12
10.5
25400
8490
0
550
0
0
0
0
0
2520
0
816
0
0
0
0
1945
0
0
0
0
0
0
0
4.23
2.44
0.00*
0.00*
3.10
2.61
0.00*
0.00*
2.99
0.00*
0.00*
0.00*
SIV, M. tuberculosis south Indian strain
Mai, M. avium intracellulare
cfu, colony forming units
* 0.00 actually means that there was no growth in culture and implies that the log cfu in spleen was less than 1.85 which was the
minimum detectable level in these experiments
in guineapigs there is no interference to theprior exposure to NTM, and a few organisms
immunity due to BCG by prior exposure to NTMdisseminate to the spleen. What happens after this
in the early coupe of challenge infection. In theseime point cannot be ascertained from the present
animals, as in BCG vaccinated animals, thestudy, but need studies with longer experimental
challenge infection is well contained during theduration for an answer. It is also possible that
early course of infection and very few organismsmultiple exposures to NTM could prevent the
reach the spleen from where they are eliminated inwaning off of immune response resulting from a
a few wk. However, at the later stages of thesingle exposure. The dissemination taking place
infection, as seen by the spleen viable counts at 12during the later course of infection may probably
wk, it appears that the barrier at the localised sitebe prevented by such multiple exposures. Multiple
of infection may not be intact in the animals withsmall dose exposure to tubercle bacilli, as happens
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in nature, may also lead to different results.
Further studies are needed to examine these
possibilities.
Based on evidence which indicates that BCG
vaccination protects humans by interfering with
the haematogenous spread of bacilli, Wiegeshaus
and Smith22 have proposed that a rational animal
model  is o n e  i n which interferencewith
haematogenous spread of bacilli is measured in
animals infected by the respiratory route with
 small numbers of bacilli as occurring in human
beings. The animal model used in the present
study differs from the rational model in that
respiratory route has not been used. Further, the
effect of multiple small dose exposure has not
been studied. However, because of its design this
model also measures only the changes in the
haematogenous spreadof  bac i l l i  and thus
protection.
Various mechanisms could be responsible for
the modulation seen during the later course of
infection in the animals exposed to NTM first
followed by BCG vaccination and then challenged.
At the initial stages, these animals are able to
contain the challenge infection to the site of
inoculation. However, at these sites the challenge
organisms might multiply later and reach high
local concentrations.The delayed type hyper-
sensitivity (DTH) could then become harmful and
cause tissue destruction and release of bacilli23.
It is also possible that the small numbers of
organisms detected in the spleen at 12 wk after
challenge could be dormant bacilli released from
the local site from time to time. Lowrie and
Andrew24 suggest that it has become increasingly
possible that immunological activation of macro-
phages, apart from resulting in killing, can also
result in reduced intracellular mycobacterial
multipl ication leading to stasis. In such a
situation,the beneficial effect of cytotoxic
lymphocytes in resistance, could be through the
release of bacilli from cells in which they are
dormant so that they become exposed to the
killing mechanisms24.
As proposed by Collins25, suppressor cells may
be responsible for the inability of the host
defences to recognise the continuing presence of
sensitising antigens of the organism and thus
contribute to the persistence of infection within
t  apparently normal immunocompetent host. As
proposed by Tsumyguchi et al26, infection with
NTM could generate suppressor cells which act by
inhibiting interleukin 2 (IL-2) production or, as
Ellner and Wallis27 propose, exaggerated produc-
tion of IL-1 may be part of the mechanism of
suppression.
The results of the present study thus suggest
tha  certain modulation of the protective immunity
due to BCG was probably taking place in animals
exposed to NTM first. However, these results
have to be confirmed in a larger scale study. In
populations of endemic areas of tuberculosis with
high prevalence of NTM, prior exposure to NTM
may have similar modulation over the immunity
due to BCG in the later course of infection. This
may explain, at least partly, the varying efficacy of
BCG seen in the different vaccination trials.
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